Skip to content
Home/How we work/Partnerships/J&J Innovative Medicine signs first-of-its-kind agreement with Yale School of Medicine’s Open Data Access Project

J&J Innovative Medicine signs first-of-its-kind agreement with Yale School of Medicine’s Open Data Access Project

Share Article
Share to
slide-images/yale-open-data-project.jpg

Janssen Research & Development (R&D) signed a first-of-its-kind agreement with Yale School of Medicine’s Open Data Access (YODA) Project to facilitate the sharing of clinical trials data aiming to enhance public health and advance science and medicine. The project represents a new standard for responsible, independent clinical data sharing. YODA independently reviews and makes final decisions regarding all requests from investigators and physicians looking to access Janssen’s anonymized clinical trials data and clinical study reports. The agreement marked the first time any company has collaborated with a completely independent third party to review and make final decisions regarding every request for clinical data.

We are delighted that through the agreement with YODA, we can share clinical trial and participant-level data in a systematic and objective way that advances medicine and scientific knowledge while protecting patient privacy and confidentiality.”
William N. Hait, M.D., Ph.D.
Global Head, Janssen R&D

Sharing anonymized data from clinical trials is critical to advance public health because it furthers understanding of diseases, expands the base of knowledge needed to develop new treatments and generates new insights and more complete evidence to enable better healthcare decisions for patients, all while protecting patient privacy and confidentiality. The YODA agreement exemplifies Janssen’s continued commitment to science, medicine and public health by creating a standardized independent, transparent and reproducible process for sharing our clinical trial data. Since the announcement in January 2014, the Yale Open Data Project has also launched a new website to assist researchers who request access to data from Janssen’s clinical trials.